The x-linked hypophosphatemia market size is projected to expand from USD 0.89 billion in 2025 and USD 0.96 billion in 2026 to USD 1.43 billion by 2031, registering a CAGR of 8.22% between 2026 to 2031. This report is Segmented by Treatment Type (Burosumab, Oral Phosphate Supplements, and More), Route of Administration (Sub Cutaneous, Oral, and More), Age Group (Infants and Toddlers, Children Aged 1-12 Years, and More), End User (Paediatric Endocrinology Centres, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).
Oral phosphate supplements and active vitamin D analogs remained relevant where reimbursement restricted biologic use, though long-term conventional treatment carried renal risks such as nephrocalcinosis and hypercalciuria. Orthopedic and supportive care remained necessary for patients with established skeletal deformities. Kyowa Kirin’s next-generation subcutaneous candidate, KK8123, entered a Phase 1/2 dose-escalation study in adults in October 2024, with an estimated completion date of May 2028. Early-stage gene transfer and minicircle DNA approaches indicated continued investment beyond antibody-based treatment.
Subcutaneous treatment held 74.34% of the route of administration segment in 2025. Its position reflected Crysvita’s established subcutaneous regimen and the revised adult dosing options approved in May 2026. Self-administration programs helped reduce clinic visit burden for families and adult patients, while intravenous and perioperative support retained limited roles in acute hospital and surgical settings.
Oral treatment is projected to grow at a CAGR of 10.80% through 2031, supported mainly by phosphate supplement formulations. Interest in oral treatment also reflects the potential development of future small-molecule FGF23 pathway modulators. No approved oral FGF23-targeted therapy is currently available, so oral conventional treatment will remain important where biologic access is restricted.
Europe is the second-largest geographic area for the X-linked hypophosphatemia market, with burosumab reimbursed for pediatric and adult patients in France, Germany, Italy, Spain, and the United Kingdom. NICE recommended burosumab for adults in August 2024 and required NHS commissioning within 3 months. The July 2026 European Commission decision extended treatment eligibility to infants aged 1 month to 1 year. Adult reimbursement still lagged in several Southern and Eastern European countries, while compassionate use remained an access route in some settings.
Asia-Pacific is projected to grow at a CAGR of 9.58% through 2031, supported by Japan’s established reimbursed XLH program and Kyowa Kirin’s Crysvita prefilled syringe launch there on November 19, 2025. South Korea and Australia added to the regional opportunity, while a Phase 4 study in Chinese children reported that burosumab corrected serum phosphorus and improved clinical outcomes. The Middle East and Africa and South America represented smaller emerging areas, with access shaped by specialist capacity and public funding. Brazil served as a regional commercial base, while wider access in Argentina and other countries relied on expanded access programs, leaving meaningful geographic variation across the X-linked hypophosphatemia market.
Global X-linked Hypophosphatemia Market Trends and Insights
Expanding Genetic and Biochemical Diagnosis
Rare disease gene panel testing can confirm XLH before patients enter long treatment pathways, supporting demand in the X-linked hypophosphatemia market. An Italian pediatric study estimated mean annual XLH prevalence at 1.78 per 100,000 registered patients, within the European registry range of 1.07 to 4.8 per 100,000. Molecular testing identified a pathogenic PHEX variant in 88.7% of clinically diagnosed patients in a multicenter testing program. This confirmation can move patients from clinical suspicion to specialist referral and treatment planning. Family cascade testing can also identify undiagnosed relatives, while better access to sequencing and telemedicine may extend these pathways beyond major specialist centers.Earlier Pediatric Intervention With FGF23 Inhibition
The European Commission approved burosumab for infants aged 1 month to 1 year in the EU and EEA on July 21, 2026. The BUR-CL207 Phase 1/2 study supported the decision and extended orphan market exclusivity to February 2030. Earlier treatment may reduce the skeletal burden that later requires orthopedic care. A 3-year disease monitoring program involving 139 children and adults reported improvements in biochemical markers, patient-reported outcomes, and physical performance with burosumab. Real-world evidence also links treatment to monitoring for nephrocalcinosis, an important complication in this patient group. These findings support treatment decisions focused on clinical outcomes across childhood rather than short-term phosphate correction alone.High Annual Biologic Cost and Reimbursement Friction
High biologic costs continue to restrict access in the X-linked hypophosphatemia market, particularly in countries without established public reimbursement. NHS Wales cited a United Kingdom list price of GBP 3,000 per vial for burosumab. Canada’s Drug Agency reported an incremental cost-effectiveness ratio of USD 1,680,920 per quality-adjusted life year for adults and concluded that the treatment was not cost-effective at standard thresholds without a price reduction. Confidential discounts and prolonged reimbursement negotiations can delay access after approval, while conventional treatment remains a lower-cost option where biologic funding is unavailable.Other drivers and restraints analyzed in the detailed report include:
- Growing Adult Recognition and Label Expansion
- Burden Reduction From Avoided Surgery and Complications
- Diagnostic Delay and Specialist Scarcity
Segment Analysis
Burosumab held 68.88% of the treatment type segment in 2025 and is projected to expand at a CAGR of 9.15% through 2031. Its leadership reflected its position as the only approved targeted therapy for XLH. Ultragenyx reported USD 481 million in global Crysvita revenue in fiscal 2025, a 17% increase from 2024, and USD 275 million from the United States and Canada royalty component.Oral phosphate supplements and active vitamin D analogs remained relevant where reimbursement restricted biologic use, though long-term conventional treatment carried renal risks such as nephrocalcinosis and hypercalciuria. Orthopedic and supportive care remained necessary for patients with established skeletal deformities. Kyowa Kirin’s next-generation subcutaneous candidate, KK8123, entered a Phase 1/2 dose-escalation study in adults in October 2024, with an estimated completion date of May 2028. Early-stage gene transfer and minicircle DNA approaches indicated continued investment beyond antibody-based treatment.
Subcutaneous treatment held 74.34% of the route of administration segment in 2025. Its position reflected Crysvita’s established subcutaneous regimen and the revised adult dosing options approved in May 2026. Self-administration programs helped reduce clinic visit burden for families and adult patients, while intravenous and perioperative support retained limited roles in acute hospital and surgical settings.
Oral treatment is projected to grow at a CAGR of 10.80% through 2031, supported mainly by phosphate supplement formulations. Interest in oral treatment also reflects the potential development of future small-molecule FGF23 pathway modulators. No approved oral FGF23-targeted therapy is currently available, so oral conventional treatment will remain important where biologic access is restricted.
Complete Report Scope:
- By Treatment Type
- Burosumab
- Oral Phosphate Supplements
- Active Vitamin D Analogs
- Combination Conventional Therapy
- Orthopaedic and Supportive Interventions
- Emerging Gene, Cell, and Nucleic-Acid Therapies
- By Route of Administration
- Subcutaneous
- Oral
- Intravenous and Perioperative Support
- By Age Group
- Infants and Toddlers
- Children Aged 1-12 Years
- Adolescents Aged 13-17 Years
- Adults Aged 18 Years and Older
- Transition-Age Patients
- By End User
- Paediatric Endocrinology Centres
- Adult Endocrinology and Metabolic-Bone Clinics
- Nephrology Clinics
- Orthopaedic Hospitals
- Dental and Craniofacial Centres
- Genetic-Medicine Centres
- Homecare Settings
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America held 39.89% of the global X-linked hypophosphatemia market in 2025, supported by the United States, which had the longest-standing burosumab approval and a broad pediatric indication covering patients from 6 months of age. Specialty pharmacy distribution supported access after physician initiation. Ultragenyx reported USD 275 million in Crysvita royalty revenue from the United States and Canada in fiscal 2025. In May 2026, Ontario, British Columbia, Saskatchewan, Alberta, and the federal Non-Insured Health Benefits program began publicly funding burosumab for eligible adults, while Mexico contributed less due to limited specialist infrastructure.Europe is the second-largest geographic area for the X-linked hypophosphatemia market, with burosumab reimbursed for pediatric and adult patients in France, Germany, Italy, Spain, and the United Kingdom. NICE recommended burosumab for adults in August 2024 and required NHS commissioning within 3 months. The July 2026 European Commission decision extended treatment eligibility to infants aged 1 month to 1 year. Adult reimbursement still lagged in several Southern and Eastern European countries, while compassionate use remained an access route in some settings.
Asia-Pacific is projected to grow at a CAGR of 9.58% through 2031, supported by Japan’s established reimbursed XLH program and Kyowa Kirin’s Crysvita prefilled syringe launch there on November 19, 2025. South Korea and Australia added to the regional opportunity, while a Phase 4 study in Chinese children reported that burosumab corrected serum phosphorus and improved clinical outcomes. The Middle East and Africa and South America represented smaller emerging areas, with access shaped by specialist capacity and public funding. Brazil served as a regional commercial base, while wider access in Argentina and other countries relied on expanded access programs, leaving meaningful geographic variation across the X-linked hypophosphatemia market.
List of Companies Covered in this Report:
- Alexion Pharmaceuticals, Inc.
- Amgen
- Ascendis Pharma A/S
- AstraZeneca
- Bayer
- Chiesi Farmaceutici
- Daiichi Sankyo
- Eli Lilly and Company
- Roche
- Inozyme Pharma, Inc.
- Ipsen Pharma SAS
- Kyowa Kirin
- Kyowa Kirin Holdings B.V.
- Mitsubishi Tanabe Pharma
- Novartis
- Pfizer
- Regeneron Pharmaceuticals
- Sanofi
- Swedish Orphan Biovitrum AB
- Takeda Pharmaceuticals
- Ultragenyx Pharmaceutical Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 INTRODUCTION
4 MARKET LANDSCAPE
5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)
6 COMPETITIVE LANDSCAPE
7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alexion Pharmaceuticals, Inc.
- Amgen Inc.
- Ascendis Pharma A/S
- AstraZeneca PLC
- Bayer AG
- Chiesi Farmaceutici S.p.A.
- Daiichi Sankyo Company, Limited
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Inozyme Pharma, Inc.
- Ipsen Pharma SAS
- Kyowa Kirin Co., Ltd.
- Kyowa Kirin Holdings B.V.
- Mitsubishi Tanabe Pharma Corporation
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
- Sanofi
- Swedish Orphan Biovitrum AB
- Takeda Pharmaceutical Company Limited
- Ultragenyx Pharmaceutical Inc.
